# US 2010/0063060 A1 · Therapeutic agent for glaucoma comprising Rho Kinhase inhibitor and prostaglandin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063060 A1
- Document ID: US20100063060A1
- Status: Published application
- Kind: A1
- Application number: 12/589,004
- Filed: 2009-10-16
- Published: 2010-03-11
- Earliest claimed: 2002-08-29
- Assignees: Santen Pharmaceutical Co., Ltd.
- Inventors: Tadashi Nakajima; Takeshi Matsugi; Hideaki Hara
- Web page: https://patentgrep.com/patent/US20100063060A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A combination of a Rho kinase inhibitor and a prostaglandin as a therapeutic agent for treating glaucoma. The actions of reducing intraocular pressure are complemented and/or enhanced by combining a Rho kinase inhibitor with a prostaglandin. Each of the Rho kinase inhibitor and the prostaglandin can be administered in combination or in a mixture.

## Claims

### Claim 1

A therapeutic composition for treating glaucoma comprising a combination of pharmaceutically effective amounts of drugs consisting essentially of (i) a Rho kinase inhibitor or a salt or an ester thereof and (ii) a prostaglandin or a salt or ester thereof, and optionally a pharmaceutically acceptable carrier.

### Claim 2

A therapeutic composition for treating glaucoma which comprises a combination of pharmaceutically effective amounts of drugs consisting essentially of (i) a Rho kinase inhibitor or a salt or an ester thereof and a (ii) prostaglandin or a salt or an ester thereof, wherein the actions of the Rho kinase inhibitor and the prostaglandin are complemented and/or enhanced by each other, and optionally a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The therapeutic composition for treating glaucoma as claimed in claim 1, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane carboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

### Claim 4 (depends on 1)

The therapeutic composition for treating glaucoma as claimed in claim 1, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

### Claim 5 (depends on 2)

The therapeutic composition for treating glaucoma as claimed in claim 2, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

### Claim 6 (depends on 2)

The therapeutic composition for treating glaucoma as claimed in claim 2, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

### Claim 7 (depends on 3)

The therapeutic composition for treating glaucoma as claimed in claim 3, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

### Claim 8 (depends on 5)

The therapeutic composition for treating glaucoma as claimed in claim 5, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.
